Pain as an indicator of bone metastasis

Area of Science:

• Oncology
• Nuclear Medicine
• Pain Management

Background:

• Skeletal pain is a frequent complaint in cancer patients.
• Bone scintigraphy is routinely used to detect metastatic bone disease.
• The relationship between skeletal pain and bone metastases requires further clarification.

Purpose of the Study:

• To evaluate the prevalence and characteristics of skeletal pain in patients with breast or prostate cancer undergoing bone scintigraphy.
• To determine the reliability of pain as an indicator for the presence and location of bone metastases.

Main Methods:

• Patients with breast or prostate cancer referred for bone scintigraphy were surveyed using a self-administered questionnaire to assess skeletal pain.
• Bone scintigraphy results were correlated with reported pain locations and presence of metastatic disease.

Main Results:

• Over half of all patients reported skeletal pain, irrespective of metastatic disease presence.
• A significant proportion of patients with bone metastases (21% breast, 22% prostate) were asymptomatic.
• Pain was reported in a minority of metastatic sites (23% breast, 15% prostate).
• Metastases were identified in only about half of the painful sites.

Conclusions:

• Skeletal pain is not a reliable indicator for the presence or location of metastatic bone disease in breast and prostate cancer patients.
• Bone scintigraphy remains crucial for diagnosing bone metastases, as pain is an unreliable marker.
• Further research into the multifactorial causes of pain in cancer patients is warranted.